Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cencora Inc

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) (the “Company”) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) (“Cencora”) common stock pursuant to variable prepaid forward transactions executed in reliance on Rule 144 under the Securities Act of 1933, as amended, for current proceeds of approximately $424 million and, depending on the stock price at the time, potentially additional proceeds at maturity. In addition, and subject to the closin.

Walgreens Boots Alliance Sells Shares of Cencora, Inc. for $674 Million of Initial Proceeds

Walgreens has been investing billions into its new healthcare business. The company only expects it to be profitable on an adjusted basis this fiscal year.

1 Big Problem With Walgreens Boots Alliance's Healthcare Strategy

Salesforce

NVIDIA

Bristol-Myers

Crown Castle International

Citizens Financial Group

Comerica

Eversource Energy

KeyCorp

Moderna

Pfizer

Charles Schwab

J. M. Smucker

Truist Financial

Tapestry

Stocks' yearly performance rankings are a field day for contrarians: One year's worst often are the subsequent year's best, and vice versa.

Why this Dow stock went from worst in 2022 to first in 2023 — and 13 turnaround candidates for 2024

CVS Health

CVS (CVS) and Walgreens (WBA) shares lost ground Wednesday after IAM Healthcare, a subsection of the International Association of Machinists and Aerospace Workers (IAM), launched The Pharmacy Guild, an effort to unite pharmacy workers who are calling for staffing and workload safety standards.

CVS and Walgreens Shares Fall After Pharmacy Guild Launches With Call to Unionize

Enphase Energy

Illumina

JD.com

Sirius XM Holdings Inc

One knock against Wall Street analysts is they're too bullish, especially when it comes to Nasdaq 100 stocks. No matter the market conditions, they seem able to find the silver lining.

6 Nasdaq 100 Stocks Down 40% or More that Will Soar As Much 367%

The Pharmacy Guild aims to help staff unionize to address what employees have called unsafe working conditions, including at Walgreens and CVS.

Pharmacy walkout organizers help launch national push to unionize pharmacists, technicians

AbbVie

Amcor Plc

Franklin Resources

Cincinnati Financial

Chevron

Essex Property Trust

Federal Realty Investment Trust

Medtronic

NextEra Energy

Realty Income Corp

Target

T. Rowe Price Group

Exxon Mobil

"Dividend Aristocrats in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years. "-- Kiplinger.com/Investing. 66 Aristocrats, screened as of November 6, 2023, represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 22.29%-34.44% topped-by O & WBA.

4 Dividend Aristocrats Signal Buys In November As 6 Await

The Dogs of the Dow strategy highlights the potential for high-quality turnaround stories among the market's laggards. With Chevron doubling down on oil in an era inching toward renewables, and 3M mired in legal settlements, investors should watch these struggling Dow components with a cautious eye.

Is It Time To Buy the Dow Jones' 3 Worst-Performing Stocks This Year?

2022 was a dreadful year for investors with the S&P 500 down almost 20% and the Nasdaq lower by a stunning 33%, and what a difference a year can make.

The 7 Highest Yielding Dividend Aristocrats You Can Buy and Hold Forever

Amgen

Boeing

Disney

Dow Inc

Goldman Sachs

Johnson & Johnson

JPMorgan Chase & Co

Coca-Cola

Merck

Verizon

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.”–Dow Jones & Co. The highest-yield 10 stocks are November's Dogs of the Dow: JNJ, AMGN, KO, GS, CVX, IBM, DOW, MMM, VZ, and WBA averaged a 5.02% annual yield. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated November net-gains ranged 19.78%-35.37%, topped by WBA 11/2/23.

November Dogs Of The Dow: 3 Buyable, 4 Watchable

Abbott Labs

Archer-Daniels-Midland Company

Automatic Data Processing

Aflac

Albemarle

A. O. Smith

Air Products and Chemicals

Atmos Energy

Becton, Dickinson and Co.

Brown & Brown

Cardinal Health

Caterpillar

Chubb

Colgate-Palmolive

Clorox

Cintas Corp

Dover

Ecolab

Con Ed

Emerson Electric

Expeditors International of Washington

General Dynamics

Genuine Parts

W.W. Grainger

Hormel Foods

Illinois Tool Works

Kimberly-Clark

New Linde PLC

Lowe's

McDonald's

McCormick

Nordson

Nucor

The highest yield isn't everything when it comes to finding the best dividend stocks. Income investors know there's no substitute for regular dividend increases over the long haul.

67 Best Dividend Stocks for Dependable Dividend Growth

News for Walgreens Stock (WBA)